Continuous Monitoring
continuous monitoring
PhenoSign - Molecular Dynamic Insights
Do You Know Your Blood Glucose Level? You Probably Should! A single measurement is not enough to truly understand your metabolic health. Blood glucose levels fluctuate dynamically, and meaningful insights require continuous monitoring over time. But glucose is just one example. Many other molecular concentrations in the body are not static. Their variations are influenced by individual physiology and overall health. PhenoSign, a Swiss MedTech startup, is on a mission to become the leader in real-time molecular analysis of complex fluids, supporting clinical decision-making and life sciences applications. By providing real-time, in-situ molecular insights, we aim to advance medicine and transform life sciences research. This talk will provide an overview of PhenoSign’s journey since its inception in 2022—our achievements, challenges, and the strategic roadmap we are executing to shape the future of real-time molecular diagnostics.
Personalized medicine and predictive health and wellness: Adding the chemical component
Wearable sensors that detect and quantify biomarkers in retrievable biofluids (e.g., interstitial fluid, sweat, tears) provide information on human dynamic physiological and psychological states. This information can transform health and wellness by providing actionable feedback. Due to outdated and insufficiently sensitive technologies, current on-body sensing systems have capabilities limited to pH, and a few high-concentration electrolytes, metabolites, and nutrients. As such, wearable sensing systems cannot detect key low-concentration biomarkers indicative of stress, inflammation, metabolic, and reproductive status. We are revolutionizing sensing. Our electronic biosensors detect virtually any signaling molecule or metabolite at ultra-low levels. We have monitored serotonin, dopamine, cortisol, phenylalanine, estradiol, progesterone, and glucose in blood, sweat, interstitial fluid, and tears. The sensors are based on modern nanoscale semiconductor transistors that are straightforwardly scalable for manufacturing. We are developing sensors for >40 biomarkers for personalized continuous monitoring (e.g., smartwatch, wearable patch) that will provide feedback for treating chronic health conditions (e.g., perimenopause, stress disorders, phenylketonuria). Moreover, our sensors will enable female fertility monitoring and the adoption of more healthy lifestyles to prevent disease and improve physical and cognitive performance.
The impact of warning cues on target-discriminating decisions in continuous monitoring situations
FENS Forum 2024